BN83495 in Prostate Cancer
| Status: | Completed |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/17/2019 |
| Start Date: | January 2009 |
| End Date: | February 2011 |
A Phase I Dose Escalating Study Evaluating the Pharmacodynamic Profile and Safety of BN83495 in Patients With Prostate Cancer With Evidence of Disease Progression While on Androgen Ablative Therapy
The purpose of the study is to evaluate the pharmacodynamic profile and safety of BN83495 in
patients with prostate cancer with disease progression while on androgen ablative therapy
patients with prostate cancer with disease progression while on androgen ablative therapy
Evaluate the PD profile of BN83495 after 28 days of daily oral administration in patients
with locally advanced or metastatic prostate cancer on androgen ablative therapy and with
rising prostatic specific antigen
with locally advanced or metastatic prostate cancer on androgen ablative therapy and with
rising prostatic specific antigen
Inclusion Criteria:
- Confirmed and locally advanced or metastatic prostate cancer with rising
prostate-specific antigen (PSA), while on androgen ablative therapy.
- Over age 18.
- Demonstrated PSA "biochemical failure".
- Adequate bone marrow and hepatic function
Exclusion Criteria:
- Luteinizing Hormone-Releasing Hormone analogue treatment and treated with more than
one additional second line of endocrine therapy
- Prior treatment with ketoconazole
- Prior chemotherapy for hormone refractory prostate cancer
- Pre-existing cardiac failure and/or clinically significant abnormal ECG or Echo
We found this trial at
3
sites
600 Highland Ave
Madison, Wisconsin 53792
Madison, Wisconsin 53792
(608) 263-6400
University of Wisconsin Hospital and Clinics UW Health strives to meet the health needs of...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials